ATC Group: J07BC01 Hepatitis B, purified antigen

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J07BC01 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J07 Vaccines
3 J07B Viral vaccines
4 J07BC Hepatitis vaccines
5 J07BC01 Hepatitis B, purified antigen

Active ingredients in J07BC01

Active Ingredient Description
Hepatitis B, purified antigen

Hepatitis B vaccine induces specific humoral antibodies against hepatitis B virus surface antigen (anti-HBsAg). Hepatitis B vaccine has been recognized as the first anti-cancer vaccine because it can prevent primary liver cancer.

Related product monographs

Title Information Source Document Type  
ENGERIX-B Suspension for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
FENDRIX Suspension for injection European Medicines Agency (EU) MPI, EU: SmPC
HBVAXPRO Suspension for injection European Medicines Agency (EU) MPI, EU: SmPC
HEPLISAV B Solution for injection in pre-filled syringe European Medicines Agency (EU) MPI, EU: SmPC
RECOMBIVAX HB Suspension for injection FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicines in this ATC group

United States (US)

Canada (CA)

Cyprus (CY)

Finland (FI)

France (FR)

Hong Kong (HK)

Israel (IL)

Italy (IT)

Malta (MT)

Netherlands (NL)

New Zealand (NZ)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.